Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 5, 1997, Pages 692-696

  Cremers, Bodo ^a   Flesch, Markus ^a   Südkamp, Michael ^a   Böhm, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Calcium antagonists; Heart failure; Human myocardium; Mibefradil; Nifedipine; Verapamil

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL; NIFEDIPINE; VERAPAMIL;

ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HEART MUSCLE CONTRACTILITY; HEART PAPILLARY MUSCLE; HEART VENTRICLE WALL; HUMAN; HUMAN TISSUE; INOTROPISM; MUSCLE ISOMETRIC CONTRACTION; PRIORITY JOURNAL;

BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; ELECTRIC STIMULATION; HEART VENTRICLES; HUMANS; MIBEFRADIL; MYOCARDIAL CONTRACTION; NIFEDIPINE; PAPILLARY MUSCLES; TETRAHYDRONAPHTHALENES; VERAPAMIL;

EID: 0030999687     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199705000-00019     Document Type: Article

References (20)

1. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-61.
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
3. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation 1991;84:2598-600.
4. Schwinger RHG, Böhm M, Erdmann E. Negative inotropic properties of isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardial tissue. J Cardiovasc Pharmacol 1990;15:892-9.
5. Yasky J, Ferrario CM. Nocturnal hypotension and ACE inhibitors. J Hum Hypertens 1993;7:299-304.
6. Becker RC, Caputo R, Ball S, Corrao JM, Baker S, Gore JM. Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration. Am Heart J 1993;126: 11-4.
7. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989;80:59-67.
8. Ferlinz J, Citron PD. Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure. Am J Cardiol 1983;51:1339-45.
9. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (Davit-II) and other recent studies. Am J Cardiol 1991;67:1295-7.
10. Dibner-Dunlap ME, Thames MD. Abnormalities of baroflex control in heart failure. Heart Failure 1990;6:12-6.
11. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989;13:754-9
12. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-8.
13. Böhm M, Diet F, Pieske B, Erdmann E. Screening of positive inotropic agents in isolated cardiac preparations from different sources. J Pharmacol Methods 1989;21:33-4.
14. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 1980;46:1047-58.
15. Bean BP. Classes of calcium channels in vertebrate cells. Annu Rev Physiol 1989;51:367-84.
16. Hermsmeyer K. Differences of calcium channels in vascular muscle in hypertension. Am J Hypertens 1991;4:412-55.
17. 2+-currents in cultivated aortic myocytes. Biochim Biophys Acta 1992;1160:95-104.
18. Neveu D, Quignard JF, Fernandez, A, Richard S, Nargeot J. Differential β-adrenergic regulation and phenotypic modulation of voltage-gated calcium currents in rat aortic myocytes. J Physiol 1994;479(2):171-82.
19. McAllister RG, Kirsten EB. The pharmacology of verapamil. IV. Pharmakokinetics and drug effects after single intravenous and oral doses in normal subjects. Clin Pharmacol Ther 1982;31: 418-26.
20. Clozel JP, Osterrieder W, Kleinbloesem CH, et al. Ro 40-5967: a new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991;9:4-17.